Last edition
News about "Frontotemporal dementia"
Denali Regains Full Rights to DNL593 After Takeda Ends Collaboration
The biotech firm will independently advance its investigational therapy for frontotemporal dementia, with Phase I/II trial results expected by 2026.
Frontotemporal Dementia | 08/04/2026 | By News Bureau | 103
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members